Armata Pharmaceuticals, Inc.
ARMP
$1.42
$0.06815.04%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -19.18% | 142.69% | -- | 21.36% | 45.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -19.18% | 142.69% | -- | 21.36% | 45.39% |
| Cost of Revenue | 2.76% | 124.31% | 2.62% | -16.53% | 243.00% |
| Gross Profit | -3.83% | 145.14% | -16.43% | 19.96% | -267.39% |
| SG&A Expenses | 4.53% | -9.46% | 46.34% | 25.22% | 75.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.01% | 10.10% | 12.30% | -7.81% | -2.39% |
| Operating Income | -10.02% | 5.61% | -23.73% | 9.85% | 7.25% |
| Income Before Tax | 113.10% | 82.41% | 353.34% | -72.68% | -92.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 113.10% | 82.41% | 353.34% | -72.68% | -92.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 113.10% | 82.41% | 353.34% | -72.68% | -92.43% |
| EBIT | -10.02% | 5.61% | -23.73% | 9.85% | 7.25% |
| EBITDA | -9.40% | 6.64% | -23.38% | 10.84% | 7.90% |
| EPS Basic | 113.08% | 82.46% | 352.80% | -72.29% | -92.17% |
| Normalized Basic EPS | -24.60% | -7.70% | -49.97% | -5.65% | -6.15% |
| EPS Diluted | 4.67% | 82.46% | -45.96% | -72.29% | -89.91% |
| Normalized Diluted EPS | 23.71% | -7.70% | -45.99% | -5.65% | -6.15% |
| Average Basic Shares Outstanding | 0.23% | 0.26% | 0.24% | 0.22% | 0.16% |
| Average Diluted Shares Outstanding | 63.66% | 0.26% | 3.01% | 0.22% | 0.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |